glucagon-like peptide-1 (GLP-1) Archive — Page 2 of 3
-
October 6, 2022
Stress, obesity and food intake
Vanderbilt researchers are elucidating the neuronal pathways that contribute to food consumption in response to stress — “comfort feeding” — and how they differ in males versus females and in the context of obesity. -
February 10, 2022
New insights into hypothalamic obesity
A common Type 2 diabetes treatment being tested for hypothalamic obesity had unexpected results on weight loss and total energy expenditure, Vanderbilt researchers report. -
October 28, 2021
Pancreatic beta-cell booster
Blocking inflammatory signaling improves beta-cell characteristics in a mouse model of type 2 diabetes and may provide added benefits to GLP-1R diabetes medications. -
May 20, 2021
Type 2 diabetes medication shown to benefit asthma patients
Type 2 diabetes patients who also have asthma are benefitting from a diabetes medication, typically given to help the pancreas produce more insulin, that also improves asthma symptoms and may reduce lung and airway inflammation. -
February 18, 2021
Gene variant and glucose metabolism
Genetic variation that impacts glucose- and insulin-related signaling affects responses to type 2 diabetes treatments and warrants further study. -
November 3, 2020
New treatment for a rare obesity
Diabetes drugs known as GLP-1 receptor agonists, such as exenatide (Byetta), are a promising and safe treatment for a rare form of obesity. -
January 10, 2019
Bile acids mediate metabolic benefits of weight-loss surgery
A team of Vanderbilt investigators has pinpointed the role of bile acids and a specific signaling pathway in the positive metabolic effects of weight-loss surgery.